Dasgupta Suryasarathi, Navarrete Ana-Maria, Delignat Sandrine, Wootla Bharath, Andre Sebastien, Nagaraja Valakunja, Lacroix-Desmazes Sebastien, Kaveri Srinivas V
INSERM, UMR S 872, Les Cordeliers, Paris F-75006, France.
Immunol Lett. 2007 May 15;110(1):23-8. doi: 10.1016/j.imlet.2007.03.006. Epub 2007 Apr 13.
A number of diseases are treated by passive administration of human proteins. Human coagulation factor VIII (FVIII) is one such protein which is administered to hemophilia A patients in order to manage and treat hemorrhagic incidences. This mode of therapy suffers from the side effect of generating anti-FVIII antibodies (inhibitors) which neutralizes the function of the infused FVIII. At a time when efficient viral screening procedures are at place, development of inhibitors poses the greatest threat to such a therapy. Various predisposing factors, both patient and product-related, are responsible for the development of inhibitory antibodies. A proper understanding of these "risk-factors" would eventually help to better design therapeutic regimen to tackle hemophilia A.
许多疾病通过被动给予人类蛋白质来治疗。人凝血因子VIII（FVIII）就是这样一种蛋白质，它被给予甲型血友病患者以管理和治疗出血事件。这种治疗方式存在产生抗FVIII抗体（抑制剂）的副作用，该抗体可中和注入的FVIII的功能。在有高效病毒筛查程序的当下，抑制剂的产生对这种治疗构成了最大威胁。各种与患者和产品相关的易感因素是抑制性抗体产生的原因。正确理解这些“风险因素”最终将有助于更好地设计治疗方案来应对甲型血友病。
